Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18842802 | 0.92 | KDM1A (0.55) | KDM1AKCNH2 | |
| SCHEMBL20129783 | 0.84 | KDM1A (0.46) | KDM1AHRH3CYP11B1CYP11B2KCNH2 | |
| SCHEMBL18849093 | 0.83 | KDM1A (0.49) | KDM1AKCNH2 | |
| SCHEMBL20129788 | 0.78 | KDM1A (0.48) | KDM1AHRH3CYP11B1CYP11B2KCNH2 | |
| SCHEMBL20129789 | 0.78 | KDM1A (0.47) | KDM1ACYP11B1CYP11B2KCNH2 | |
| SCHEMBL18842800 | 0.76 | KDM1A (0.51) | KDM1AHRH3CYP11B1CYP11B2KCNH2 | |
| SCHEMBL20129781 | 0.76 | KDM1A (0.42) | KDM1AHRH3CYP11B1CYP11B2KCNH2 | |
| SCHEMBL20129790 | 0.75 | KDM1A (0.43) | KDM1AHRH3KCNH2 | |
| SCHEMBL20129787 | 0.74 | KDM1A (0.42) | KDM1AHRH3CYP11B1CYP11B2KCNH2 | |
| SCHEMBL20129791 | 0.74 | KDM1A (0.42) | KDM1AHRH3CYP11B1CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885HRH3 1906/4885CYP11B1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.